Clinical characteristics of At-Risk progressors at 12 months
| Clinical criteria | Baseline | 12 months |
| (n=19) | (n=19) | |
| Mucocutaneous | ||
| ACLE or SCLE | 5/19 (26%) | 13/19 (68%) |
| Mucosal ulcers | 2/19 (11%) | 8/19 (42%) |
| Alopecia | 0 | 4/19 (21%) |
| Musculoskeletal | ||
| Synovitis | 9/19 (47%) | 18/19 (95%) |
| Haematological | ||
| Leucopaenia or lymphopenia | 3/19 (16%) | 7/19 (37%) |
| Thrombocytopenia | 0 | 1/19 (5%) |
| Glandular signs | 0 | 6/19 (32%) |
| Serositis | ||
| Pleural effusion | 0 | 1/19 (5%) |
| Renal | ||
| Class III nephritis | 0 | 1/19 (5%) |
ACLE, acute cutaneous lupus erythematosus; SCLE, sub-acute cutaneous lupus erythematosus.